Analysis of the efficacy and safety of Saccharomyces boulardii in the treatment of pediatric diarrhea
10.13699/j.cnki.1001-6821.2024.17.025
- VernacularTitle:布拉氏酵母菌治疗儿童腹泻的有效性和安全性分析
- Author:
Li-Li MOU
1
,
2
;
Xiao-Dan ZHANG
;
Lu LIU
;
Chun-Hong CHEN
;
Zhuo CHEN
;
Hui YIN
;
Mei-Xing YAN
Author Information
1. 青岛大学药学院,山东青岛 266000
2. 日照市中心医院药学部,山东日照 276800
- Keywords:
Saccharomyces boulardii;
combined Bacillus subtilis and Enterococcus faecium enteric-coated;
Bifidobacterium triple live bacteria;
Bifidobacterium tetragenous viable;
pediatric diarrhea;
Meta-analysis
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(17):2575-2579
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and safety of Saccharomyces boulardii and other probiotics in the treatment of pediatric diarrhea.Methods Retrieved from PubMed,Embase,CBM,Wanfang data,CNKI and VIP,randomized controlled trial(RCTs)about Saccharomyces boulardii(treatment group)vs other probiotics(control group)were collected.After screening the literature,extracting data and evaluating the quality,Meta-analysis was performed by using RevMan 5.3 and Stata 17.0 software.Results A total of 30 RCTs were included,involving 3 082 children.Results of Meta-analysis showed there was no statistical significance in the duration of diarrhea[mean difference(MD)=-0.65,95％confidence interval(CI)=-1.44-0.14,P＞0.05]or the total incidence of adverse reactions[odds ratio(OR)=0.85,95％CI=0.44-1.62,P＞0.05].The total effective rate(OR=1.60,95％CI=1.08-2.36,P＜0.05)and the number of stools(MD=-0.66,95％CI=-1.00--0.32,P＜0.01)in the treatment group were significantly better than control group.There was statistically significant difference in the duration of diarrhea between the two groups treated with diarrhea with fever(MD=1.81,95％CI=1.12-2.49,P＜0.01)and rotavirus gastroenteritis(MD=-0.92,95％CI=-1.20--0.64,P＜0.01).In the treatment of diarrhea with fever,the duration of diarrhea in the control group was significantly shorter than that in the treatment group.The duration of diarrhea in the treatment group was significantly shorter than that control group.At the same time,the duration of diarrhea in children with diarrhea treated with treatment group was significantly shorter than that of control group Bifidobacterium tetragenous viable(MD=-0.84,95％CI=-1.09--0.58,P＜0.01)and control group combined Bacillus subtilis and Enterococcus faecium enteric-coated(MD=-1.35,95％CI=-2.30-0.39,P＜0.01).Conclusion The safety of Saccharomyces boulardii are similar to other probiotics.The efficacy and the number of stools with Saccharomyces boulardii are significantly better than other probiotics in the treatment of diarrhea.The duration of diarrhea in Saccharomyces boulardii group was significantly shorter than other probiotics,while in the treatment of antibiotic-associated diarrhea,the duration of diarrhea of Saccharomyces boulardii was the same as that of other probiotics.However,the duration of diarrhea in children with diarrhea treated with Saccharomyces boulardii was significantly longer than other probiotics.
